News | February 02, 2024
Morepen Laboratories reports Q3 FY24 consolidated PAT at Rs. 31.99 Cr
Morepen Laboratories has reported total income of Rs. 448.62 crores during the period ended December 31, 2023
Morepen Laboratories has reported total income of Rs. 448.62 crores during the period ended December 31, 2023
Morepen Laboratories has reported total income of Rs. 425 crores during the quarter ended September 30, 2023
The company is addressing these observations
The company posted net profit of Rs.19.36 crores for the period ended June 30, 2020.
The company posted net profit of Rs.19.36 crores for the period ended June 30, 2020.
R&D Centre will be housed in Baddi and will cater to all business divisions in addition to expansion plans for all its verticals including APls, Formulations and Medical Devices
Sharma joined the Morepen Lab in 2004
Fexofinadine is the most widely used, second-generation antihistamine drug for the treatment of allergy symptoms and hay fever
The new devices company will scale up its teams to create a world-class R&D centre for medical devices in India
The revenues and profits derived from the new subsidiary will be consolidated in the parent company
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)